Literature DB >> 32234899

Diagnostic Value of FDG-PET/CT for the Identification of Extranodal Extension in Patients With Head and Neck Squamous Cell Carcinoma.

Ryo Toya1, Tetsuo Saito2, Tomohiko Matsuyama2, Yudai Kai3,4, Shinya Shiraishi5, Daizo Murakami6, Ryoji Yoshida7, Takahiro Watakabe2, Fumi Sakamoto4, Noriko Tsuda4, Hidetaka Arimura4, Yorihisa Orita6, Hideki Nakayama7, Natsuo Oya2.   

Abstract

BACKGROUND/AIM: We evaluated the diagnostic value of functional imaging with [18F]-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography/computed tomography (PET/CT) for the identification of extranodal extension (ENE) in patients with head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: In this study, 94 patients with HNSCC who underwent FDG-PET/CT were enrolled. We recorded the maximum standardized uptake value (SUVmax), compared the results with pathologic findings, and evaluated the diagnostic performance of using a SUVmax cut-off value for ENE.
RESULTS: Of the 566 dissected levels examined, 53 (9.4%) exhibited ENE. The mean SUVmax of LN with and without ENE were 6.67 and 1.64, respectively (p<0.001). A receiver operating characteristics (ROC) curve analysis for SUVmax showed an area under the ROC curve of 0.913. A SUVmax cut-off of 3.0 achieved diagnostic performance for identifying ENE with sensitivity, specificity, and accuracy of 81.1%, 94.3% and 93.1%, respectively.
CONCLUSION: FDG-PET/CT findings using a SUVmax cut-off of 3.0 provides appropriate diagnostic value in identifying ENE. Copyright
© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Head and neck cancer; extranodal extension; lymph node metastasis; positron emission tomography; squamous cell carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32234899     DOI: 10.21873/anticanres.14165

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Predictors of Extracapsular Spread in T1/T2 Oral Squamous Cell Carcinoma: A retrospective study.

Authors:  Sapna Tandon; Rathindra Nath Bera; Akhilesh Kumar Singh; Madan Mishra
Journal:  J Oral Biol Craniofac Res       Date:  2022-05-27

2.  Diagnostic Accuracy of Combined PET/CT with MRI, 18F-FDG PET/MRI, and 18F-FDG PET/CT in Patients with Oropharyngeal and Hypopharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Mania Kave; Kambiz Sadegi; Fateme Parooie; Morteza Salarzaei
Journal:  Contrast Media Mol Imaging       Date:  2021-04-28       Impact factor: 3.161

3.  Prevalence and risk factors of retro-styloid lymph node metastasis in oropharyngeal carcinoma.

Authors:  Ryo Toya; Tetsuo Saito; Yoshiyuki Fukugawa; Tomohiko Matsuyama; Tadashi Matsumoto; Shinya Shiraishi; Daizo Murakami; Yorihisa Orita; Toshinori Hirai; Natsuo Oya
Journal:  Ann Med       Date:  2022-12       Impact factor: 4.709

4.  Impact of metal artifact reduction algorithm on gross tumor volume delineation in tonsillar cancer: reducing the interobserver variation.

Authors:  Yoshiyuki Fukugawa; Ryo Toya; Tomohiko Matsuyama; Takahiro Watakabe; Yoshinobu Shimohigashi; Yudai Kai; Tadashi Matsumoto; Natsuo Oya
Journal:  BMC Med Imaging       Date:  2022-09-06       Impact factor: 2.795

5.  Hypofractionated palliative volumetric modulated arc radiotherapy with the Radiation Oncology Study Group 8502 "QUAD shot" regimen for incurable head and neck cancer.

Authors:  Ryo Toya; Tetsuo Saito; Kohsei Yamaguchi; Tomohiko Matsuyama; Takahiro Watakabe; Tadashi Matsumoto; Ryoji Yoshida; Akiyuki Hirosue; Daizo Murakami; Yorihisa Orita; Hideki Nakayama; Natsuo Oya
Journal:  Radiat Oncol       Date:  2020-05-27       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.